中药治疗腹泻型肠易激综合征伴焦虑抑郁的机制:网络药理学与Meta分析
本研究通过Meta分析纳入25项随机对照试验共2055例患者,评估中药治疗腹泻型肠易激综合征(IBS-D)伴焦虑抑郁的疗效,并结合网络药理学探讨其机制。结果显示中药在IBS-D疗效、焦虑抑郁评分及复发率方面均显著优于对照,核心成分可能通过抗炎、抗氧化应激及神经递质稳态等途径发挥作用。
要点
- 中药可显著改善IBS-D伴焦虑抑郁患者的肠道症状及焦虑抑郁状态。
- 中药治疗组复发率显著低于对照组。
- 网络药理学提示中药活性成分可能作用于IL-6、TNF等炎性靶点。
核心结论
- 中药治疗IBS-D伴焦虑抑郁具有较好疗效和安全性,可能通过多成分多靶点发挥作用。
研究设计与样本
- 系统综述与Meta分析,纳入25项随机对照试验,共2055例患者,并结合网络药理学分析。
主要发现
- 试验组IBS-D治疗有效率显著高于对照组[OR=4.01,95%CI(2.99,5.36),I2=0%]。
- 试验组抑郁评分显著改善[SMD=-1.08,95%CI(-1.30,-0.86),p<0.00001,I2=68%;SDS:SMD=-1.69,95%CI(-2.48,-0.90),p<0.0001,I2=96%]。
- 试验组焦虑评分显著改善[HAMA:SMD=-1.29,95%CI(-1.68,-0.91),p<0.00001,I2=89%;SAS:SMD=-1.75,95%CI(-2.55,-0.95),p<0.00001,I2=96%]。
- 试验组复发率显著低于对照组[OR=0.30,95%CI(0.20,0.44),p<0.00001,I2=0%]。
- 网络药理学识别出Beta-谷甾醇、豆甾醇、槲皮素等关键代谢物及IL-6、TNF、PPARG等核心靶点。
关键数值与推荐
- 中药治疗IBS-D伴焦虑抑郁的疗效指标包括IBS-SSS及症状评分,试验组均持续改善。
临床怎么用
- 对于IBS-D伴焦虑抑郁患者,可考虑在辨证基础上使用中药治疗,以改善肠道及情绪症状并降低复发。
局限性
- 原文未报告纳入研究的偏倚风险、异质性来源及具体中药方剂组成等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of Chinese herbal medicine (CHM) in managing irritable bowel syndrome with diarrhea (IBS-D) accompanied by anxiety and depression remains uncertain. Thus, a systematic review was carried out employing meta-analysis and network pharmacology to ascertain the efficacy and underlying mechanisms of CHM therapy. METHODS: By conducting a systematic review, including literature search, screening, and data extraction, we identified 25 randomized controlled trials to assess CHM's effectiveness in treating irritable bowel syndrome alongside anxiety and depression. Network pharmacology was utilized to scrutinize the metabolite utility of CHM in addressing this condition. Potential primary mechanisms were synthesized using information sourced from the PubMed database. RESULTS: Twenty-five studies, including 2055 patients, were analyzed, revealing significant treatment efficacy for IBS-D in the trial group compared to controls [OR = 4.01, 95% CI (2.99, 5.36), I2 = 0%] Additionally, treatment for depression [SMD = -1.08, 95% CI (-1.30, -0.86), p < 0.00001, I2 = 68%; SDS: SMD = -1.69, 95% CI (-2.48, -0.90), p < 0.0001, I2 = 96%] and anxiety [HAMA: SMD = -1.29, 95% CI (-1.68, -0.91), p < 0.00001, I2 = 89%; SAS: SMD = -1.75, 95% CI (-2.55, -0.95), p < 0.00001, I2 = 96%] significantly improved in the trial group. Furthermore, the trial group exhibited a significantly lower disease relapse rate [OR = 0.30, 95% CI (0.20, 0.44), p < 0.00001, I2 = 0%]. CHM treatment consistently improved IBS severity (IBS-SSS) and symptom scores. Network pharmacology analysis identified key chemical metabolites in traditional Chinese medicine formulations, including Beta-sitosterol, Stigmasterol, Quercetin, Naringenin, Luteolin, Kaempferol, Nobiletin, Wogonin, Formononetin, and Isorhamnetin. Utilizing the STRING database and Cytoscape v3.9.0 software, a protein-protein interaction (PPI) network revealed the top eight key targets: IL-6, TNF, PPARG, PTGS2, ESR1, NOS3, MAPK8, and AKT1, implicated in anti-inflammatory responses, antioxidant stress modulation, and neurotransmitter homeostasis maintenance. CONCLUSION: Chinese Herbal Medicine (CHM) offers a promising and safe treatment approach for patients dealing with Diarrheal Irritable Bowel Syndrome (IBS-D) accompanied by anxiety and depression; thus, indicating its potential for practical implementation. The most active metabolites of CHM could simultaneously act on the pathological targets of IBS-D, anxiety, and depression.The diverse scope of CHM's therapeutic role includes various aspects and objectives, underscoring its potential for broad utilization.
引用
- Bai C, Wang J, Wang Y, et al. Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis. Front Pharmacol. 2024. PMID: 38835657. doi:10.3389/fphar.2024.1404738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。